ArticleJournal of contemporary brachytherapy2026
Enhancing brachytherapy in cervical cancer: Initial dosimetric experience and assessment of Tulip hybrid applicator - the Add-On advantage.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report initial clinical experience of the Tulip Add-On hybrid intracavitary/interstitial (IC/IS) brachytherapy applicator in locally advanced carcinoma cervix, and to compare its dosimetric performance with conventional IC brachytherapy. Material and methods: Eight patients with FIGO stage IIB-IIICr1 cervical cancer were treated between January 2021 and January 2022. All received external beam radiotherapy with concurrent chemotherapy, followed by CT-guided IC/IS brachytherapy using Henschke applicator with Tulip Add-On interstitial needles. Paired dosimetric plans (IC/IS vs. IC-only) were generated for each patient. Target coverage (D Results: Median age was 58 years; median high-risk clinical target volume (HR-CTV) was 55.6 cc (range, 25.6-81 cc). Six patients required bilateral and two unilateral interstitial insertions. Compared with IC-only, IC/IS plans significantly improved HR-CTV coverage: D Conclusions: The Tulip Add-On applicator offers superior HR-CTV coverage without compromising OARs sparing. It is a practical, resource-adaptive technique that combines simplicity of intracavitary brachytherapy with dosimetric advantages of interstitial approaches, particularly valuable for patients with residual parametrial disease post-EBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.